Global Cardiac Marker Testing Market Growth, Size, Share, Trends, and Forecast 2032
Cardiac Marker Testing Market Analysis By Type (Troponin I and T, Brain Natriuretic peptide (Bnp or Nt-Probnp), Creatine kinase-MB (CK-MB), Myoglobin, HIGH-sensitivity C-reactive protein (hs-CRP), and Other Biomarkers), By Product (Instruments, Chemiluminescence, Immunofluorescence, ELISA, Immunochromatography, Reagents and Kits), By Disease (Acute Coronary Syndrome, Atherosclerosis, Congestive Heart Failure, Myocardial Infarction, and Ischemia), By Type of Testing (Academic Institutions, Laboratory Testing, and Point-Of-Care Testing), and By Region: Global Industry Perspective, Comprehensive Analysis and Forecast, 2024-2032
| Market Size in 2023 | Market Forecast in 2032 | CAGR (in %) | Base Year |
|---|---|---|---|
| USD 4.30 Billion | USD 9.29 Billion | 9.05% | 2023 |
How big is the cardiac marker testing market?
The global Cardiac Marker Testing market size accrued earnings worth approximately USD 4,300.5 Million in 2023 and is predicted to gain revenue of about USD 9,285.1 Million by 2032, is set to record a CAGR of nearly 9.05% over the period from 2024 to 2032.
Cardiac Marker Testing Market: Overview
When the heart is injured or stressed, it releases certain substances into the blood, which function as cardiac markers. The cardiac markers are usually enzymes, proteins, and hormones. Thus, quantification of these biomarkers can aid in diagnosing numerous heart disorders, including cardiac ischemia, acute coronary syndrome, and conditions linked to hindered blood supply to the heart. Physicians usually carry out multiple cardiac marker tests for hours to observe the blood level increase and to recognize the seriousness of a heart attack.
Cardiac Marker Testing Market: Growth Factors
The major factors boosting the growth of global cardiac marker testing include rising expenditure by different institutes to encourage clinical and research studies in biomarker testing, increasing incidence of cardiovascular disorders, and increasing elderly population. However, issues related to storage and collection of samples, compensation, and strict regulatory recommendation are few factors that can hamper the growth of the global market. In addition, estimation of cardiac marker levels in the labs requires considerable time; thus, it cannot be used in the determination of myocardial infarction during the acute phase further restraining its use.
Cardiac Marker Testing Market: Report Scope
| Report Attributes | Report Details |
|---|---|
| Report Name | Cardiac Marker Testing Market |
| Market Size in 2023 | USD 4,300.5 Million |
| Market Forecast in 2032 | USD 9,285.1 Million |
| Growth Rate | CAGR of 9.05% |
| Number of Pages | 214 |
| Key Companies Covered | Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, Randox laboratories Ltd, Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories,Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem. |
| Segments Covered | By Type, By Product, By Disease, By Type of Testing, and By Region |
| Regions Covered | North America, Europe, Asia Pacific (APAC), Latin America, Middle East, and Africa (MEA) |
| Base Year | 2023 |
| Historical Year | 2018 - 2022 |
| Forecast Year | 2024 - 2032 |
| Customization Scope | Avail customized purchase options to meet your exact research needs. Request For Customization |
Cardiac Marker Testing Market: Segmentation
The global market for cardiac marker testing can be segmented based on disease, type of testing, product, type, and region. The disease segment of the market is divided into congestive heart failure and myocardial infarction. The type of testing segment of the market is diversified into point-of-care testing and laboratory testing. The product segment of the cardiac marker testing market is classified into immunofluorescence, immunochromatography, instruments, reagents and kits, chemiluminescence, and enzyme-linked immunosorbent assay. The type segment of the market is divided into C-reactive protein, troponin I and T, brain natriuretic peptide or NT-proBNP, CK-MB, other biomarkers, and myoglobin. The other biomarkers segment of the market is classified into H-FABP, homocysteine, myeloperoxidase, galectin-3, and ischemia-modified albumin. Regionally, the cardiac marker testing market is diversified into North America, Europe, Asia-Pacific, Latin America, and the Middle East & Africa.
Cardiac Marker: Regional Analysis
North America is anticipated to dominate the global market of cardiac markers testing. The various factors contributing to the growth of the market in this region include rising aging population, increasing inclination toward point-of-care testing, and elevated frequency of cardiovascular disorders. Asia-Pacific region is also expected to grow in the global market in the near future owing to the huge population, growing incidence of chronic heart diseases, and various measures taken to increase alertness about the diagnosis of cardiac diseases at an early stage.
Cardiac Marker Testing Market: Competitive Players
The key players in the global cardiac marker testing market include
- Siemens AG
- Abbott Laboratories
- Danaher Corporation
- bioMérieux SA
- Alere, Inc.
- Roche Diagnostics Ltd.
- Ortho Clinical Diagnostics
- LSI Medience Corporation
- Randox laboratories Ltd.
- Guangzhou Wondfo Biotech Co., Ltd.
- Bio-Rad Laboratories,Inc.
- Helomics Corporation
- Becton
- Dickinson and Company
- Avantra Biosciences
- and Enzo Biochem.
Segment Coverage
The global Cardiac Marker Testing Market is segmented as follows:
By Type
- Troponin I and T
- Creatine kinase-MB (CK-MB)
- Brain Natriuretic peptide (Bnp or Nt-Probnp)
- Myoglobin
- HIGH-sensitivity C-reactive protein (hs-CRP)
- Other Biomarkers
By Product
- Instruments
- Chemiluminescence
- Immunofluorescence
- ELISA
- Immunochromatography
- Reagents
- Kits
By Disease
- Myocardial Infarction
- Congestive Heart Failure
- Acute Coronary Syndrome
- Atherosclerosis
- Ischemia
By Type of Testing
- Laboratory Testing
- Hospital Labs
- Refrence Labs
- Contract Labs
- Academic Institutions
- Point-Of-Care Testing
By Region
- North America
- The U.S.
- Canada
- Mexico
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia Pacific
- The Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of the Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
Table Of Content
Methodology
FrequentlyAsked Questions
Cardiac marker testing measures specific proteins in blood. It helps diagnose heart attacks and cardiac conditions.
The global Cardiac Marker Testing market is expected to be driven by the rising cardiovascular disease prevalence and demand for early diagnosis. Advancements in point-of-care testing support market expansion.
According to study, the global Cardiac Marker Testing market size was worth around USD 4.30 Billion in 2023 and is predicted to grow to around USD 9.29 Billion By 2032.
The global Cardiac Marker Testing market is expected to grow at a Compound Annual Growth Rate (CAGR) of around CAGR 9.05% during the forecast period from 2024-2032.
The global Cardiac Marker Testing industry is projected to be challenged by Challenges include high test costs, need for rapid accuracy, and reimbursement variability.
The Opportunities include rising cardiovascular disease prevalence, emergency diagnostics demand, point-of-care testing growth, and hospital adoption will offer significant growth opportunities in the Cardiac Marker Testing market.
High-sensitivity and rapid diagnostic assays; point-of-care testing expansion; integration with digital health and emergency care workflows are the emerging trends and innovations impacting the Cardiac Marker Testing market.
The global Cardiac Marker Testing market is expected to be led by North America during the forecast period.
Some of the prominent players operating in the global Cardiac Marker Testing market are; Siemens AG, Abbott Laboratories, Danaher Corporation, bioMérieux SA, Alere, Inc., Roche Diagnostics Ltd., Ortho Clinical Diagnostics, LSI Medience Corporation, Randox laboratories Ltd, Guangzhou Wondfo Biotech Co., Ltd., Bio-Rad Laboratories,Inc., Helomics Corporation, Becton, Dickinson and Company, Avantra Biosciences, and Enzo Biochem. and others.
The report explores crucial aspects of the Cardiac Marker Testing market, including a detailed discussion of existing growth factors and restraints, while also browsing future growth opportunities and challenges that impact the market.
HappyClients
